Concord Biotech gains on getting GMP for unit II of Gujarat facility
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Concord Biotech is currently trading at Rs. 1463.65, up by 23.40 points or 1.62% from its previous closing of Rs. 1440.25 on the BSE.
The scrip opened at Rs. 1441.05 and has touched a high and low of Rs. 1477.15 and Rs. 1441.05 respectively. So far 3957 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 1608.20 on 10-Jan-2024 and a 52 week low of Rs. 900.00 on 18-Aug-2023.
Last one week high and low of the scrip stood at Rs. 1477.15 and Rs. 1370.15 respectively. The current market cap of the company is Rs. 15312.15 crore.
The promoters holding in the company stood at 44.08%, while Institutions and Non-Institutions held 15.40% and 40.52% respectively.
Ministry of Health Pharmacy and Poisons Board, Republic of Kenya has completed inspection at Concord Biotech’s Unit II (formulation facility), located at Valthera-Dholka in Ahmedabad, Gujarat. The said inspection has been completed successfully, without any adverse remarks and the company has received the certificate of Good manufacturing practices (GMP) as on February 22, 2024.
The said Unit complies with the prescribed Good Manufacturing practices as per relevant WHO technical Report Series and other internationally acceptable guidelines.
Concord Biotech is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology.
